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Pancreatic cancer (PC) is one of the most difficult illnesses to treat, since five-year survival is 
lower than 5 % in patients, and no substantial advances in its treatment have been achieved in the last 
twenty years. Since cancer deregulation and progression are associated with changes in at least one 
biochemical pathway, the knowledge of the structure of the proteins involved in such routes seems to 
be crucial to understand how this cancer progresses, and more importantly to design more efficient 
rationally designed drugs. In this review, we describe the fold and structures of proteins involved in 
different signalling pathways which intervene during PC development and progression. In particular, 
we will focus on the most frequently mutated, or alternatively differently expressed, proteins in PC. 
The current knowledge suggests that most of the proteins carry out their function by interacting with 
others via specific domains, and through key residues at the recognition interfaces; these amino acids 
are mutated in patients developing PC. Furthermore, phosphorylation seems to be a crucial regulation 
step along several signalling pathways. Finally, we show that not only well-folded protein in several 
signalling pathways are critical in the development of PC, but also natively-unfolded “hub” proteins, 
able to interact with DNA or proteins, are also important in such cancer progression.  
 
SYNOPSIS 
Although pancreatic cancer (PC) accounts for a roughly 3 % of deaths in all cancers, it remains an 
important health problem, since no significant improvement in its treatment has been achieved in the 
last twenty years. The knowledge of the structure of proteins involved in PC can be important to 
understand at the molecular level the causes behind cancer development, and to rationally design 
better drugs. We describe the fold, scaffold and structure (when available) of the most relevant 
proteins known to intervene at different stages of pancreatic cancer and which are involved in different 
signalling pathways. The results shown suggest different approaches to tackle PC. 
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INTRODUCTION 
Pancreatic cancer (PC) is the fifth most common cause of death in Western countries [1,2]. 
When it is detected, a 90 % of patients show metastatic infiltration in proximal lymph nodes, liver or 
lungs. The current five-year survival is roughly a 2-3 % [2,3]; in the best cases, when surgical 
removal is possible (roughly in a 10 % of reported cases), the survival rate increases to 20 %. 
Unfortunately, radiation and chemotherapy do not increase significantly the rate of survival. 
Mutations and deregulations of tumour suppressors (such as p53 and BRCA2), oncogenes, signalling 
molecules and some cell surface receptors are known to be involved during the development of PC 
[4,5]. Although a great deal is known (see the accompanying papers in these series) about the 
specific events that take place during pancreatic carcinogenesis and the effect of several antibodies, 
limited structural information is available for most of the proteins involved in PC. The knowledge of 
the structure of such proteins is important to decide, in conjunction with their involvement in 
specific and key protein pathways, whether they can be considered as attractive therapeutic targets. 
The three-dimensional structure of target proteins is also essential to implement and develop a 
structural-based rational drug design strategy. 
Signal transduction pathways are involved at different stages in the development of PC. Such 
pathways can be involved in tumour proliferation, resistance to apoptosis, invasion, metastasis and 
angiogenesis.  Reactivation of physiological embryonic signalling pathways is also frequent in PC. It 
has been proposed that signalling pathways altered in tumorogenesis or cancer progression, represent 
promising potential targets for the development of future therapies. Therefore, in this review, we will 
focus on genes frequently mutated, or differentially expressed at any stage during the development 
of PC, that play an important role in the signalling pathways up-regulated in such illness. This 
approach can exclude some relevant proteins such as p53 [6], metalloproteases [7] or telomerases 
[8], which also intervene in PC [9,10], but they are not exclusive from PC and their structures have 
been extensively described elsewhere [6,7,11,12]. We will focus on the fold, domain architecture 
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and structure (when it is known) of individual proteins intervening in signalling pathways in PC, 
rather than on the signalling pathways themselves. We also describe the structure of the complexes 
formed with other interacting protein partners along the signalling pathway. The review is written 
for the layman, since we have attempted to convey all the terms clearly, trying not to introduce 
expert concepts on structural folds and protein domains, or when required for the description, the 
terms are firstly explained. The description of each protein has a brief introduction describing its 
importance in PC, and the signalling pathway where it intervenes. Description of the structure of the 
isolated protein follows (when available), and in some cases, the description of the complexes with 
other biomolecules along the corresponding signalling pathway, to show the importance of key 
residues at the recognition interfaces during PC development. We have divided the proteins 
described in two types: (i) those multidomain ones whose structure, or that of their isolated domains, 
is known; and, (ii) those (1) proteins acting as natively-unfolded “hubs” in protein networks, and 
those (2) whose three-dimensional structure has not been solved at the time of writing this review. 
Our conclusions based on the gathered data suggest that: (i) proteins involved or related with 
PC, and whose structure is known, are homo or hetero-oligomeric species, which are involved in 
complex signalling pathways; (ii) when the structure of the complex between the protein and its 
target in a signalling pathway is known, mutations important in the development of PC appeared 
clustered around the recognition binding site, suggesting new clues to the development of more 
efficient rationally designed drugs; (iii) phosphorylation seems to be an important step for 
modulation of the activity of many of the proteins described, and interestingly enough, the tryrosine 
kinase domain is widely extended among the proteins involved in PC development, showing the 
importance of posttranslational modifications, and then, the use of kinases as possible therapeutic 
targets [13]; and, (iv) the proteins, whose three-dimensional structures are solved, are involved in 
several other malignant tumours suggesting that the lack of PC specific targets might be the reason 
for the limited effect of the current available therapies. 
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PROTEINS WITH A KNOWN STRUCTURE 
In the following, we shall describe the three-dimensional structure of proteins involved in PC 
development. In particular, we shall focus on some of the most frequently mutated or differentially 
expressed proteins in PC which are involved in up-regulation of signalling pathways.  
Most of the proteins described below consist of several domains which fold independently. 
The most common domain found is the tyrosine kinase. Due to its importance and since protein 
kinase pathways have been described as possible drug targets [13], we first describe briefly this 
domain (Fig. 1). It is structurally divided into two lobes, the amino terminal one is formed almost 
entirely by β-strands which are covered on one side by an α-helix; the movement of this helical 
region is critical to acquire the active conformation of the catalytic site. The C-terminal lobe is 
formed almost entirely by α-helices, with a short two-stranded β-sheet. Between the lobes, the 
catalytic cleft is located; this cleft is capped on one site by the catalytic loop and on the other by the 
activation loop; the latter is relocated by phosphorylation, and then it modulates the activity of the 
kinase. 
Hepatocyte growth factor receptor (HGF receptor Met receptor) 
HGF receptor is an integral plasma membrane receptor tyrosine kinase over-expressed in 78% 
of pancreatic cancers [14]. It is the receptor for HGF and the scatter factor; the HGF receptor is 
involved in cell proliferation, scattering, multicellular organism development and survival. HGF 
receptor is a proto-oncogene produced as a 1390-amino-acid single-chain precursor; the protein is 
cleaved by the cellular protease furin between residues 307 and 308 to yield a disulfide-linked two-
chain heterodimer formed by two chains (of 50 and 145 kDa). The intact protein is fomed by: (i) a 
Sema domain (a variation of the β-propeller topology (see below), which is characterized by a set of 
conserved cysteines, forming four disulphide bridges); (ii) a PSI domain (a cysteine-rich domain 
which is formed by a three-stranded antiparallel β-sheet and two α-helices); and, (iii) three, or four, 
IPT/TIG (immunoglobulin-like fold) domains, and an intracellular domain that includes a protein 
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tyrosine kinase domain. There are available structures of each isolated domain, which are described 
in the following.  
The structure of the protein tyrosine kinase domain (residues 1049-1360) shows the well-
known fold of protein kinases (see above) [15]. Kinase activation is achieved through 
autophosphorylation of tyrosines 1234 and 1235 in the activation loop (the so-called A loop). There 
is a conserved tandem-tyrosine polypeptide patch containing a multifunctional docking site at the C 
terminus of the domain (the so-called supersite: Y1349VHVNATY1356VNV), which is absolutely 
required for signalling both in vitro and in vivo. The first part of the motif (formed by Y1349VHV) 
has an extended conformation, whereas the second part (Y1356VNV), which is also a binding site for 
SH2 domains (see below the description of such domains), folds as a type II β-turn. The N1353ATY 
region assumes a type I β-turn conformation. The phosphorylated Tyr1349 and Tyr1356 residues 
serve as docking sites for a wide spectrum of transducers and adaptors, including PI3K, Src, Grb2, 
Shc, Gab1, and Stat3 proteins. The corresponding signalling complex triggers the intracellular 
downstream effects, including cell proliferation, scattering, and inhibition of apoptosis. There are 
also structures of the domain with organic compounds [15]; for instance, the furanosylated 
indolocarbazole K-252a -it belongs to a family of microbial alkaloids, which also includes 
staurosporine- inhibits autophosphorylation, and it is bound into the adenosine pocket (formed, 
among others, by the following residues of the domain: Ile1084, Phe1089, Val1092, Ala1108, 
Lys1110, Leu1157, Met 1211 and the patch formed by Ala1226 to Tyr1230). The binding mode of 
alkaloid is analogous to that of staurosporine, and then, this site can be considered a good target 
recognition site.   
The three-dimensional structure of the c-Cbl tyrosine kinase-binding (TKB) motif of the HGF 
receptor (residues 997-1009) [16] has also been solved. Cbl proteins appear to have two major 
physiological functions: acting as protein scaffolds, or in targeting proteins for ubiquitination. c-Cbl 
interacts with a diverse array of proteins via : (i) its phosphorylatable tyrosine residues located at its 
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C terminus; (ii) its proline-rich region; and, (iii) its N-terminal phosphotyrosine-like binding domain, 
close to a RING domain. This phosphotyrosine binding domain structurally resembles an SH2 
domain (see below a structural description of the domain), with an additional flanking four-helix 
bundle, and a subdomain to accomplish binding. Together, these three sub-domains make up the 
TKB domain, which is unique to Cbl proteins. Binding to the TKB domain of HGF receptor is 
needed for the subsequent conjugation of ubiquitin; binding occurs between a phosphotyrosine and 
the conserved asparagine or the adjacent arginine of the TKB domain, directing the target 
polypeptide patch towards a positively charged pocket on c-Cbl. 
The structure of the extracellular domain of HGF has also been solved (residues 25-740 of the 
intact HGF) [17]; this region includes the Sema domain, the PSI domain and two IPT/TIG domains 
(immunoglobulin-like fold). The structure of the complex formed by this region and the surface 
protein of the human pathogen Listeria monocytogenes suggests that binding to the extracellular 
domain of HGF could occur through the first immunoglobulin-like and Sema domains; however, it is 
important to keep in mind that the cell surface protein of Listeria  is not a structural mimic of HGF.  
The structure of the isolated PSI domain (519-562) has also been solved by NMR [18]. The 
structure represents a cysteine knot with short regions of secondary structure including a three-
stranded antiparallel β-sheet and two α-helices. All eight cysteines are involved in disulfide bonds. It 
is suggested that the PSI domain could be a wedge between the propeller domain (Sema) and 
immunoglobulin (IPT/TIG) domains [18], and it seems to be responsible for the correct positioning 
of the receptor-binding site in the Sema motif. 
Cholecystokinin B (CCK-B) and gastrin receptor 
The CCK-B frequency of expression in PC is 95 %. CCK-B is the receptor for gastrin (see 
below). In general, CKK-B receptors occur throughout the central nervous system, mediating its 
action by binding to G-proteins [19,20]. There are three known isoforms. The largest 516-residues-
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long isoform 2 is present in pancreatic and colorectal cancer cells, but not in normal pancreas or 
colonic mucosa [21].  
The CCK-Bs are formed by several transmembrane domains (TM), connected by 
cytoplasmatic or extracellular loops, typically containing 50-80 residues. There are no structures of 
the whole protein, but there are three-dimensional ones in aqueous solution (NMR) in complex with 
other CCK regions and always within a lipid environment. For instance, the conformation of 
CCK(A)-R(1-47) (the fragment comprising residues 1 to 47 of the CCK-A) consists of a well-
defined α-helix (residues 3-9) followed by a β-sheet stabilized by a disulfide bridge leading to the 
first TM α-helix [22]. The structure of the third extracellular loop (residues 352 to 379) of the human 
cholecystokinin-2 receptor, CCK2-R(352-379), consists of three helices, with the first and third ones 
corresponding to the extracellular ends of TM helices 6 and 7 of the whole protein, respectively [23]. 
The central helix (residues 363-368) is associated to the dodecylphosphocholine micelles used in the 
NMR studies. Upon titration of CCK-8 with the receptor domain, several NMR parameters show the 
formation of a stable complex and specific ligand/receptor interactions, suggesting the involvement 
of the TM helix 7. These results differ from other structural studies of CCK-8, where the association 
involved the TM helix 6. These differences might: (i) play a role in the ligand specificity displayed 
by the different CCK receptor subtypes; or alternatively, (ii) suggest the influence of the membrane 
mimetics used.  
To conclude the structure of the CCK/gastrin receptors, as inferred by the isolated polypeptide 
regions whose structures are available, appears to be formed mainly by α-helices. 
Sonic hedgehog (SHH) and Indian hedgehog (IHH) proteins 
The secreted morphogen Hedgehog (Hh) protein and its highly conserved homologs are 
involved in cellular differentiation during embryogenesis either in invertebrates and vertebrates. In 
mammals, there are three Hh genes, which encode the Sonic hedgehog (Shh), the Indian hedgehog 
(Ihh) and Desert hedgehog (Dhh) proteins. They are involved in processes such as neural tube, 
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branching morphogenesis, bone formation and spermatogenesis. Although Hh signalling is mostly 
inactive in adults, it has been implicated in many cancers. Shh is expressed in 70% of human 
pancreatic adenocarcinomas [24] and Ihh expression is increased thirty-five-fold in PC cells 
compared to normal tissues [25]. 
In spite of having a metalloprotease-like protein fold, Shh acts as a ligand for membrane-
bound receptors rather than as a protease. The transmembrane protein Patched (Ptc1) is a negative 
regulator of the Hh pathway, which, in the absence of ligand, prevents Hh signalling by repressing 
the transmembrane protein Smoothened (Smo). Binding of Shh to Ptc1 relieves the inhibition of 
Smo, allowing translocation to the primary cilium, where down-stream signalling events lead to the 
activation of a family of zinc finger transcription factors. Smo is a G-protein coupled receptor 
protein which is conserved from flies to humans, and it can work as an oncogene. Hedgehog-
interacting protein (Hhip, also known as Hip) is also a negative regulator of the pathway, and it is 
up-regulated in response to Hh signalling, such as that occurring in the presence of Ptc1. The 
decreased expression of human Hhip has been noted in several tumour types, suggesting a potential 
role for Hhip in tumour suppression. The Shh protein contains two domains, the Hh amino-terminal 
signalling domain and the C-terminal Hint (Hedgehog/Intein) that has been split into an N-terminal 
and C-terminal regions to accommodate large insertions of endonucleases.  
Structures of the Hh amino-terminal signalling domain isolated, and forming complexes with 
several partners have been solved. The structures differ among the members of the family, but 
essentially they contain a large antiparallel β-sheet [26], which can be covered on one side by two α-
helices [27]. The structure of the Hhip in complex with Shh has also been solved. The Hhip is 
formed by two EGF domains (see below the description of this domain) and a six-bladed β-propeller 
domain (this domain is a type of all-β protein fold characterized by four to eight blade-shaped β-
sheets arranged toroidally around a central axis). The three-dimensional structure shows that a loop 
of Hhip binds a groove of Shh where a Zn2+ cation is present [28], coordinated by several histidine 
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and aspartic residues. The comparison of Ptc1 sequences across the species reveals a sequence motif 
that is similar to this loop in Hhip, suggesting a similar way of inhibition of the Hh signalling, and 
then, a function in tumour progression. 
Vascular endothelial growth factor (VEGF) 
The angiogenesis involves the growth of new blood vessels from pre-existing ones, and 
tumours need a constant supply of nutrients through blood vessels. Angiogenesis is mediated in solid 
growth tumour by the vascular endothelial growth factor family (VEGF) of proteins and receptors. 
The regulation of lymph vessel formation by VEGFs occurs through activation of three receptor 
tyrosine kinases (see above): VEGFR-1, -2, and -3. In addition, VEGF signalling is modulated 
through interactions with other co-receptors, such as heparan sulfate proteoglycans and neurophilins 
[29]. VEGFs have multiple isoforms which are generated by alternative splicing and 
posttranslational processing displaying distinct receptor specificities. Over-expression of VEGFs in 
PC is larger than 90 % [30]. 
Six isoforms of VEGF are expressed in humans having 121, 145, 165, 183, 189, or 206 
residues in each monomer. The various isoforms have in common an N-terminal receptor-binding 
domain, whereas the longer isoforms (having 165 to 206 residues) also include a 50-residue heparin-
binding domain at the C-terminal region. The structure of the heparin binding domain has been 
solved for VEGF165, and it has two subdomains, each containing two disulfide bridges and a short 
two-stranded antiparallel β-sheet, where heparin is anchored [31,32].  VEGF binds to, and induces 
dimerization of, the tyrosine kinase receptors Flt-1 (fms-like tyrosine kinase-1) and KDR (kinase 
insert domain). Dimerization of KDR and Flt-1 occurs through symmetric binding to a pair of 
receptor-binding sites, at the poles of the receptor-binding domain of dimeric VEGF. Binding to 
KDR results in stimulation of vascular endothelial mitogenesis; on the other hand, binding to Flt-1 
induces organizational effects on the vasculature. Structures have been published for several isolated 
VEGF and/or their complexes with tyrosine kinase receptors, antibodies or peptides [33-36] 
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Humanized neutralizing monoclonal antibodies against VEGF result in shrinkage of tumours; the 
binding sites of several such neutralizing antibodies have been shown to overlap with the KDR- and 
Flt-1-binding sites on the VEGF receptor-binding domain [37]. Antagonist peptides against VEGF 
also bind to the same regions as antibodies, KDR or Flt-1 [38].The VEGFs whose structures have 
been reported to date are antiparallel, eight-residue-ring cystine-knot polypeptide dimers that are 
covalently linked by at least two intermolecular disulfide bonds [39,40]; however, in mature VEGF-
C, a mixture of covalently and non-covalently bound dimers has been described [41].  
The common cystine-knot domain of VEGF isoforms is formed by an antiparallel four-
stranded β-sheet, three connecting loops (L1–L3), and an extended N-terminal α-helix (α1). 
Receptor specificity is determined by the N-terminal α-helix and the three peptide loops (Fig. 2), 
which form the receptor-binding domain for dimeric VEGF. In some VEFGs, the cystine-knot 
homology domain is flanked by C- and N-terminal pro-peptides, which are sequentially cleaved, 
giving rise to VEGF homologs with distinct functions.  
Src proteins 
Src is one of the members of the Src family kinases (SFKs) which are non-receptor protein 
tyrosine kinases, reported to be critical for cancer progression; in fact, the Src family is one of the 
preferred targets for clinical development of new drugs (see [13] and references therein). Src is the 
product of the first proto-oncogene characterized [42], and it works as a protein switch. The output is 
the tyrosine phosphorylation, and the input is the multiple protein-protein interactions occurring 
through several regions of its structure. Further, Src family members appear to respond to receptor-
mediated signals, either by changes in kinase activity, or by alterations in cellular location. 
Phosphorylated Src is inactive under healthy conditions, but 70% of pancreatic cancers show the 
active form [43]. The main consequence of increased c-Src activity in tumour cells is to reduce cell 
adhesion, facilitate motility, and thereby promoting an invasive phenotype. The c-Src kinase activity 
is an important component of the invasive phenotype in both early and advanced solid tumours. In 
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early disease, c-Src kinase plays a key role in the epithelium to mesenchymal transition that marks 
the conversion of epithelial tumor cells to a more invasive phenotype. The increased c-Src kinase 
activity has been linked with the disruption of E-cadherin-mediated cell-cell adhesion, and affects 
the assembly and turnover of focal adhesions, which are critical for cell migration and cancer 
metastasis.  
From a structural point of view, Src is a multidomain protein.  It consists of an N-terminal SH3 
domain followed by an SH2 one. A tyrosine kinase catalytic domain is present at the C-terminus (see 
above). The SH2 and SH3 domains are involved in protein-protein interactions at several signalling 
cascades, and they are also found in other families outside of the Src family (see above for other 
proteins containing those domains). SH3 domains are involved, either as isolated individual proteins 
or as portions of larger ones, in signal transduction and protein-protein recognition processes. The 
SH3 fold is composed of a compact β-barrel of five anti-parallel β-strands; the five strands form two 
orthogonal β-sheets of three strands, with one strand shared by both sheets; at one of the ends of the 
strand there is a small helical region (Fig. 3). Functional studies have shown that these β-barrel 
modules have a non-polar groove complementary to peptides in a polyproline II conformation 
[44,45]; furthermore, the proline-rich polypeptide patches in other proteins are also involved in 
interactions with SH3-containing modules. The SH2 domain consists of a β-sheet which is flanked 
on either side by two α-helices. SH2 domains bind polypeptide regions containing a 
phosphotyrosine, with a high specificity towards the residues following such phosphotyrosine. 
There is a structure available of a large fragment of a Src protein [46,47] in the phosphorylated 
and un-phosphorylated forms, showing the switch mechanism of the protein. Phosphorylation of the 
tyrosine at the C terminus creates an intermolecular binding-site for the SH2 domain, locking the 
molecule in an inactive state; this movement concomitantly disrupts the kinase active site and 
sequesters the binding surfaces of the SH2 and SH3 domains. There are also several structures 
available for the individual SH3 domains [48].  
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Epidermal Growth factor receptor (EGFR)  
The human EGF receptor (EGFR) is a 1186 amino acid transmembrane glycoprotein. It is 
involved in the control of cell growth and differentiation. EGFR homo- or hetero-dimerizes with 
other members of the ErbB protein family, and thus, recruiting intracellular proteins activating the 
signalling EGFR cascade [49,50], the percentage of altered or over-expressed EGFRs in PC is 
between 20-50 % [50]. It phosphorylates the protein Muc 1 in breast cancer cells and increases the 
interaction of Muc 1 with c-Src (see above) and β-catenin (see below) [51]. Epidermal growth 
factors (EGF) regulate cell differentiation and proliferation by binding to the EGF receptor (EGFR) 
extracellular region, with the resultant dimerization of the receptor tyrosine kinase domain. In fact, 
EGFR can be considered as a transmembrane receptor tyrosine kinase with two domains.  The 
extracellular portion is the 622-residue N-terminal region which is divided into four articulated 
subdomains, I–IV, which are Furin-like reapeats. Domains I and III share 37% amino acid identity, 
whereas domains II and IV are homologous Cys-rich domains. Domains I and III have the β-helix or 
solenoid topology expected from the sequence-related extracellular region of the insulin-like growth 
factor-1 (IGF-1) receptor [52] (see below for a structural description of this domain). The cysteine-
rich domains II (amino acids 166-309) and IV (amino acids 482–618) contain a succession of small 
disulphide-bonded modules with an extended rod-like structure. Two types of disulphide-bonded 
module are seen in each domain. In one type (C1), a single disulphide bond constrains a bow-like 
loop. In the other (C2), two disulphide bonds link four successive cysteines to yield a knot-like 
structure. The domain II contains three consecutive C2 modules followed by five C1 modules. On 
the other hand, domain IV contains seven disulphide-bonded modules [53]. Finally, the intracellular 
domain of EGFR contains a protein tyrosine kinase domain.  
Three-dimensional structures of EGFRs are available for the extracellular domain (residues 25-
646) in complex with several ligands (see, for instance [54]) and also for the isolated tyrosine kinase 
domain (residues 712-968) ([55] and references therein). The structures of the monomeric or dimeric 
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extracellular domain of EGFR [56] are not substantially altered upon binding to EGF; in fact, both 
ligand binding and dimerization occur through intramolecular domain arrangement of the Furin 
domains. For instance, in the monomeric form, the dimerization interface is occluded from the 
solvent by intramolecular interactions among domains II and IV [56], without changing the overall 
fold of each domain. Upon binding to EGF, the domains I–III of EGFR are arranged in a C- shape, 
and EGF is docked between the Furin domains I and III. The 1:1 EGF-EGFR complex dimerizes 
through a direct swapped receptor-receptor interaction, in which a protruding β-hairpin arm of each 
EGFR domain II extends to hold the body of the other [57]. In that arrangement, the two cytoplasmic 
tyrosine kinase domains of the receptors are close enough for autophosphorylation, and the, they 
activate the intrinsic tyrosine kinase activity. The EGFR tyrosine kinase domain is able to trigger 
numerous down-stream signalling pathways, like other receptor tyrosine kinases and tyrosine kinase-
linked cytokine receptors [58]. The extracellular region of EGFR is thought to modulate the 
spontaneous oligomerization observed in some cases when tyrosine phosphorylation occurs. 
β-Catenin protein 
The Wnt-β-catenin signalling pathway is involved in cell-cell adhesion, epithelial to 
mesenchymal transition, embryonic development, tumorigenesis and regulation of angiogenesis. The 
pathway is down-regulated in the adult organs, and alteration of the signalling cascade has a big 
impact in tumour progression and metastasis. Thus, accumulation of β-catenin is a hallmark of 
several cancers (and among them, PC, where accumulation of the protein occurs in 65 % of the cases 
[59]). As β-catenin accumulates in the cell, it forms a complex with members of the Tcf family 
transcription factors and activates the transcription of several critical genes involved in cell 
proliferation. Then, disruption of such interactions should provide a way to treat several cancers. 
The β-catenin is a 781-residues long protein, whose sequence contains several armadillo/beta-
catenin-like repeats. The three-dimensional fold of the protein shows that twelve repeats form a 
superhelix of alpha helices with three helices per unit (Fig. 4) (where the 42-amino acid sequence is 
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the armadillo repeat unit). The cylindrical structure has a positively charged groove, at repetitions 5 
to 9 of the armadillo motif, with two highly conserved lysines (the so-called charged “buttons”), 
where the Tcf transcription factors are anchored via two acidic residues. Mutation of either the 
lysines in the armadillo unit or the aspartic residues in the Tcf domain abolishes binding [60]. The 
crystal structure of β-catenin in complex with the N-terminal region of the Tcf3 domain from 
Xenopus showed that the complex has an elongated structure that extends along the positively 
charged superhelical groove formed by the β-catenin armadillo repeats [60] (Fig. 4). Binding in the 
Tcf3 transcription factor occurs through three binding modules: a β-hairpin module in the N-
terminus, an extended central region that adopts a β-strand conformation, and a C-terminal α-helix. 
The structures of complexes of β-catenine with other Tcf transcriptional factors have also been 
solved and show a similar structural arrangement [61]. Interestingly enough, binding of the ICAT 
protein (a biomolecule which hampers the interaction between β-catenin and the Tcf family 
transcription factors) occurs through the groove formed by armadillo repeats 5 to 9 of β-catenin, but 
also via the 10 to 12 armadillo repeats [62], indicating that binding can take place at different 
positions of the armadillo structure. 
Focal adhesión kinase (FADK) 
The FADK is a 1052-residue-long cytoplasmic multi-domain protein involved in cell junction 
cell motility and survival; it is over-expressed in 48% of pancreatic cancers [63]. Analysis of the 
primary structure of FADK shows that it contains an N-terminal ERM domain responsible for 
plasma membrane localization. The ERM domain family is formed by ezrin, radixin and moesin 
proteins (and so, the name of the family); each domain consists sequentially of: (i) an N-terminal 
globular region; (ii) an extended α-helical region; and, (iii) a highly charged C-terminal region, 
which in some proteins also encompasses a polyproline patch following the α-helical region. FADK 
also has a tyrosine kinase as catalytic domain, and a focal adhesion targeting domain towards the C-
terminus. 
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Structures are available for the focal adhesion targeting domain (residues 891-1052). Its 
overall structure is an antiparallel four-helix bundle with an up-down, up-down, right-handed 
topology [64,65]. There are short loop regions connecting this unusual parallel arrangement. The 
leucine-rich hydrophobic core of the domain also contains a methionine zipper from helices 1 and 4; 
these two helices are also tethered by two salt-bridges (involving aspartic and arginine residues); but, 
the helical bundle seems to be quite flexible since some crystal structures form swapped domains by 
intervening the N-terminal region and the first helix [65]. The Tyr925, which is phosphorylated by 
members of the Src kinase family, is located at the N-terminus of helix 1. The structure of the 
tyrosine kinase domain of FADK (residues 411-689) has also been solved and shows the described 
fold (see above) [66].  
AKT2 protein 
AKT2 or protein kinase B is a serine/threonine protein kinase in the PI3K-Akt pathway 
capable of phosphorylating several proteins and activating down-stream targets such as mTOR or 
NFkB. The AKT2 protein is activated by PI3K upon activation by Ras or alternatively by EGFR. It 
is over-expressed in 20% of pancreatic cancers [67].  
The analysis of the AKT2 primary structure shows an N-terminal Pleckstrin homology (PH) 
domain for binding to inositol phosphates and PI3K. It also contains a serine/threonine protein 
kinase, catalytic domain; in fact, AKT2 phosphorylation at position Thr309 and Ser474 is required 
for full activity. An NMR structure for the PH domain and several X-Ray structures for the 
serine/threonine kinase domain have been solved. The structure of the AKT2 kinase domain [68] 
shows a protein composed of two subdomains: one is a helical motif formed by eight to nine helical 
stretches; and the second is formed by a long antiparallel β-strand, on which three α-helices are 
packed. Both domains are connected by a flexible linker, where the catalytic cleft is located. The PH 
domain shows the same structure of other members of the PH family [69]. Its fold is formed by two 
perpendicular anti-parallel β-sheets, followed by a C-terminal amphipathic α-helix. The lengths of 
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the loops between the β-strands differ among the members of the family, providing the source of the 
domain specificity.  
The cyclo-oxygenase protein (COX)  
Cyclo-oxygenases are bifunctional enzymes that catalyse the first step in the synthesis of 
prostaglandins, thromboxanes and other eicosanoids. The initial cyclo-oxygenase reaction converts 
the achiral arachidonic acid to the chiral prostaglandin G2. There are two COX isoforms (COX-1 and 
COX-2), which share a high degree of amino-acid sequence similarity, structural topology and an 
identical catalytic mechanism. The expression of COX-2 is induced by tumour promoters, cytokines 
and growth factors, and its expression is up-regulated in 90 % of pancreatic cancers [70]; conversely, 
COX-1 is constitutively expressed, and it has a homeostatic role. The mechanisms modulating 
cancer-development through COX involve: (i) several mitogenic-signalling pathways; and, (ii) 
interaction with other molecules mediating resistance to apoptosis, angiogenesis and immune-
suppression [71]. 
Both isoforms are 600-residue-long proteins, which form homodimers, where only one subunit 
of the homodimer is active at a time during the enzymatic reaction [72]. Both proteins are α-helical 
(formed by up to sixty-nine helical regions, Fig. 5) connected by short strands of a twisted β-sheet 
[73,74]. The site for the fatty acid in all the structures of solved complexes with either isoform is 
located in the so-called cyclooxygenase channel (Fig. 5). In such channel, the carboxylate of the 
substrate interacts with the guanidinium group of an arginine residue (this residue is a key 
determinant for binding of the fatty acid to COX-1 but not for COX-2 [75]), and its end region binds 
to a hydrophobic groove which is capped by a tyrosine residue. 
Insulin-like growth factor I receptor 
The insulin-like growth factor I (IGF I) receptor is a transmembrane protein, with tyrosine 
kinase activity, that plays an important role in cell growth control. The IGF I is overexpressed in 
64% of pancreatic cancers [43] and its subunit structure is formed by a tetramer of two alpha and 
 19 
two beta chains linked by disulphide bonds. The alpha chains contribute to the formation of the 
ligand-binding domain, whereas the beta chains contain the tyrosine kinase domain. 
The extracellular region of IGF I is formed by two leucine-rich repeats (forming a right-
handed β-α superhelix) with a cysteine rich domain in-between (L1-Cys-rich-L2); each of the L 
domains consists of a single-stranded right-handed β-helix, similar to the fold described for the 
extracellular domain of EGFR (see above). The three domains surround a central space of enough 
size to accommodate a ligand molecule. The extracellular region is completed with three fibronectin 
type-III domains (which have a β-sheet sandwich motif). The intracellular portion holds the catalytic 
tyrosine kinase domain. Thus, it can be concluded that the overall disposition of the domains in the 
extracellular region of IGF I is similar to that observed in the EGFR. 
Most of the available structures of IGF I describe the protein tyrosine kinase domain (see 
above). There is also a structure of the three N-terminal domains (L1-Cys-rich-L2) [76], having the 
cysteine-knot fold described above for the C2 Cys-rich domains of the extracellular domain of 
EGFR. 
SMAD family member 4 (Smad4) 
Smad4 is a 550-residue-long protein, which acts as a common mediator of signal transduction 
by TGF-β (transforming growth factor-β) superfamily of cytokines. After receptor kinase activation, 
the signals of the TGF-β family are regulated by several evolutionarily conserved proteins known as 
SMAD proteins; several SMAD proteins have been characterized in vertebrates. The Smad4 
member, also known as DPC4 (deleted in pancreatic carcinoma locus 4), has a central role in signal 
distribution by forming hetero-oligomers with other pathway-restricted SMAD proteins: Smad 1, 2, 
3, 5 and 8, which function in specific signalling pathways.  These pathway-restricted SMAD 
proteins are phosphorylated at the conserved C-terminal tail sequence, SSpXSp (where the “p” denotes 
a site of phosphorylation), by a receptor kinase, in response to TGF-β activation. The heteromeric 
complexes of Smad 4 with the phosphorylated SMAD proteins are translocated into the nucleus. In 
 20 
the nucleus, the heteromeric complexes function as gene-specific transcription activators by binding 
to promoters and interacting with transcriptional coactivators. Defects in Smad4 are a cause of 
pancreatic carcinoma [77], and mutations of the protein cause a gastrointestinal polyposis, which can 
develop gastrointestinal cancers. 
Smad4 is a multidomain protein. It contains an N-terminal DWA and a C-terminal DWB 
domains (also called MH1 and MH2 domains) separated by a variable proline-rich linker region (the 
so-called L domain); in general, all SMAD proteins share that common domain configuration 
consisting of the MH1 and MH2 domains separated by the proline-rich linker.  
The crystal structure of the MH1 domain for several pathway-restricted SMAD proteins shows 
a globular fold consisting of four α-helices (α1-α4) and short β-strands (β1–β6) connected by loops. 
The 11-residue-long β-hairpin formed by strands β2 and β3 protrudes from the core of the otherwise 
globular MH1 domain, and it is inserted into the major groove of the DNA. Recent reports from 
several pathway-restricted SMAD proteins suggest that there is not a general recognized DNA 
consensus sequence [78-80]. 
The crystal structure of the Smad4 MH2 domain (residues 319-552) suggests that the 
functional unit of SMAD proteins is trimeric. The MH2 domain forms a crystallographic trimer, 
through a conserved protein-protein interface, to which the majority of the tumour-derived missense 
mutations map [81]. Each monomer is formed by five α-helices and three loops enclosing a β-
sandwich. Mutations of the residues comprising residues 506-522 (one of the loops) disrupt the 
heteromeric interaction between Smad4 and the other pathway-restricted SMAD proteins, suggesting 
that protein-protein interactions occur via such a highly-conserved loop; interestingly enough, 
several tumour-derived mutations are also located in that region [81]. Moreover, this loop is also 
involved in the interactions of Smad4 with the members of the Ski family of proto-oncoproteins 
[82]. An additional SMAD-activation domain (SAD) is located at the N-terminal of the MH2 
domain [83,84]. In the X-ray structure of the fragment comprising the SAD and the MH2 region of 
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Smad4, the SAD region appears to form the core of the protein [85], with a large solvent-exposed 
proline-rich region. This region, together with a nearby glutamine-rich helix, is proposed to be a 
potential transcription activation surface [85]. 
p16 or INK4 protein 
p16 is a 150-residue-long protein, whose overexpression causes cell cycle arrest and inhibition 
of tumour cell proliferation in cell cultures [86]. The p16 protein functions by inhibiting the activity 
of cyclin-dependent kinase 4 (cdk4) or cdk6. When inhibited, cdk4 and cdk6 cannot phosphorylate 
several regulatory proteins, involved in the cell cycle; thus, inactivation occurs by blocking the 
association of cdk4/6 with cyclin D, preventing kinase activation, and resulting in cell cycle arrest by 
p16 [87]. This inactivation contributes to a variety of neoplasias, and interestingly enough, p16 
mutants (which lack the ability to arrest cell-growth) have been found in more than 70 different 
types of tumour cells [88,89], and they are frequently observed in PC [90]. 
The structure of p16 is characterized by a four linear (I–IV) array of a repeating structure: the 
so-called ankyrin motif [91]. Each 33-residue long ankyrin repeat exhibits a helix-turn-helix (H-T-
H) fold (with an overall shape resembling an “L”), although the first half of the second ankyrin 
repeat of p16 consists of only one helical turn; all the helices of the motif are packed into helical 
bundles. The four H-T-H motifs are connected by three loops, whose orientations are such that they 
are perpendicular to the helical axes; in that arrangement, the ankyrin-repeats stack to yield a 
concave surface on one side (in fact, this surface is formed by the entire ankyrin repeat III, the third 
loop and the N-terminal region of fourth helix in the second repetition). Mutations involved in 
several pancreatic cancers appear more frequently in the second loop. This region is also the one 
involved in binding to cdk6 [92], where the recognition between the two proteins is mediated 
primarily by hydrogen-bond networks, and thus, the overall structure of p16 is not altered upon 




The K-Ras is a 189-residue long protein, which bind GDP/GTP and possess intrinsic GTPase 
activity. In general, Ras proteins transmit extracellular signalling from receptor tyrosine kinases to 
two serine/threonine kinases (Raf and MEK) and, finally, leading to the activation of mitogen-
activated protein kinase, MAPKs. Upon nuclear import, MAPKs phosphorylate many different 
transcription factors, modulating DNA binding affinity, nuclear localization, and thereby regulating 
gene expression. Several studies demonstrate that Ras/MAPK signalling plays a role in normal 
development [93-95]; moreover, between 15 to 20% of all human tumours have an activating 
mutation in one of the three ras genes (N-, K-, or H-ras), which code for very similar proteins of 
around 21 kDa molecular mass. These proteins are post-translationally modified by the covalent 
attachment of lipophilic groups to the C terminus; this modification targets Ras proteins towards the 
plasma membrane, where their interacting proteins are found [96] Although many of the components 
of Ras/MAPK signalling have been characterized, the full array of transcription factors affected is 
not known; moreover, the detailed mechanisms by which phosphorylation modulates transcription 
factors is still unclear in many cases. The lifetime of the signal transduced by Ras proteins is 
determined by the lifetime of the GTP-bound state. These GTP-binding proteins work as molecular 
switches by cycling between GDP-bound and GTP-bound states; being the exchange of the bound 
GDP for GTP facilitated by guanine-nucleotide exchange factors. Mutant forms of the human Ras 
genes (at positions 12, 13 and 61) that yield a protein with a prolonged GTP-bound state (due to a 
smaller rate of GTP-hydrolysis) are found in human cancers [97,98]. 
The K-Ras protein appears as two isoforms, which differ at the C terminal region. Mutations in 
K-Ras are behind the onset of different leukaemia, and those mutations are also involved in the 
development of bladder, stomach, colon, cervix, brain pancreatic and lung cancers [93-95, 99-101]. 
The X-ray structures of several Ras proteins have been solved (see, for instance, [97,100] and 
references therein). The structure is composed of a six-stranded β-sheet, which is packaged on one 
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site on a five α-helical bundle; the GTP binding site involves one of the helices and a long loop 
connecting with a β-strand; the structural difference between the GDP-bound and GTP-bound states 
involves the length increase of an α-helix with is set perpendicularly to the binding site in the GTP-
bound state [100, 102-106]. 
Notch 3 protein 
Notch 3 functions as a receptor for membrane-bound ligands Jagged 1, Jagged 2 and Delta 1 to 
regulate cell-fate determination. It is expressed in around 70% of pancreatic cancers [107]. Notch 3 
is involved in the Notch signalling pathway; it forms a transcriptional activator complex and 
activates several genes, upon ligand activation through the released notch intracellular domain. In 
general, Notch 3 affects the implementation of differentiation, proliferation and apoptotic programs.  
Structurally, Notch 3 is a heterodimeric complex of a C-terminal and N-terminal fragments, 
which are probably linked by disulfide bonds. There are no three-dimensional structures available of 
Notch 3, although the structure of Notch-1-ankyrin domains and EGF domains have been solved 
([108] and references therein), and it will be described in the following. At the N-terminal 
extracellular portion of Notch 1, there are several repetitive EGF (epidermal growth factor) domains 
and three NL domains (a domain found in Notch and Lin-12 proteins with three disulphide-bridges 
and three conserved aspartate and asparagine residues). The EGF domain has three disulphide-bridge 
and it is formed by a two-stranded β-sheet followed by a loop which joins to a short two-stranded β-
sheet at the C terminus. Notch 3 also contains six ankyrin repeats in the C-terminal fragment (see 
above for a description of ankyrin motifs).  
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PROTEINS WITH AN UNKNOWN STRUCTURE OR NATIVELY UNFOLDED 
In the following, we shall describe the few structural data which are known on the structure or 
fold of other proteins involved in signalling pathways during the development of PC. The three-
dimensional structures of those proteins are not known because the proteins involved are natively 
unfolded, or alternatively because, at the day of writing this review, and although the can show a 
sequence similarity to proteins whose structure is known, there are not detailed structural reports on 
the particular protein described.   
Pancreatitis associated protein 1 
Induction of acute pancreatitis in rats showed the presence of a new protein in the pancreatic 
juice during the early stages of the illness; the protein was over-expressed in the following three to 
four days [109], and, then it was called pancreatitis associated protein (PAP). PAP is constitutively 
expressed in healthy pancreas by the α-cells of Langerhans islets [110], and it has been involved in 
the response of pancreatic cells to cell injury (see [111] for a detailed overview of the different 
functions of PAP). Interestingly enough, PAP mRNA expression was observed in pancreatic and 
hepatocellular adenocarcinomas and some of the mucinuous cystadenomas [112,113].  
PAP is a 175-residues-long polypeptide containing a carbohydrate binding domain (CBD) 
[112,113], which is the binding motif of C-type Ca2+-dependent lectins. At the N terminus of PAP, 
there is a short peptide which is cleaved during maturation [114]. Sequence similarities between 
PAP and other lectin domains range from 16 % to 26 %, and even the gene organization of PAP 
suggests that the protein belongs to a new type of lectins which have evolved from the same 
carbohydrate-recognition domain [115]; furthermore, PAP only contains the CBD, conversely to 
what happens to other lectins where additional motifs are present, and which provide the specific 
functions of lectins. Attempts to characterize a carbohydrate-binding affinity in PAP have failed 
[116], and no structural approach has been tackled. Thus, due to the high structural diversity among 
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the C-type lectins (from immunoglobulin-like folds to coiled-coils) no clues about PAP structure are 
known. 
The stress-inducible p8 protein 
The p8 (also called NUPR1 (nuclear protein-1) or Com1 (candidate of metastasis-1)) was 
firstly described as a gene induced during pancreatitis in pancreatic acinar cells [117]. The protein is 
over-expressed in several cancers, acting as a cell-stress response (see [118] for a recent review on 
p8 functions).  
High resolution structural studies by NMR, fluorescence and CD spectroscopies have shown 
that p8 is disordered [119]. Moreover, analysis of the sequence with several recent disorder 
predictors indicates that p8 belongs to the class of “natively unfolded proteins” (Fig. 6). The primary 
structure of p8 shows a large abundance of arginine, proline, serine and glycine residues, and an 
almost complete absence of disorder-promoting residues, such as leucine or valine, when compared 
to the average propensity of these residues in the PDB structures (Fig. 6 A). The use of Foldindex 
[120] indicates that regions comprising residues Ala3 to Thr9, and Ser32 to Tyr37 are the only 
ordered polypeptides patches. On the other hand, the RONN predictor [121] suggests that p8 is 
completely disordered, although the region from Asp29 to Arg43 appears less disordered than the 
rest of the polypeptide patches (Fig. 6 B). Thus, p8 is the first protein involved in PC which has been 
identified as a “natively unfolded protein”. 
The protein is able to interact with other proteins or DNA. The phosphorylated p8 interact with 
chromosomic DNA [119]. On the other hand, p8 binds to the hystone acetyltransferase-associated 
protein MSL1, contributing to chromatin rearrangement by facilitating the access to DNA of the 
transcription machinery [122]. The p8 protein also interacts with the anti-apoptotic protein 
prothymosin α, suggesting that p8 also has non-transcriptional roles [123]. The p8-prothymosin-α 
complex is able to inhibit the staurosporine-induced apoptosis. Structurally, binding occurs in 
regions close to the two tyrosine residues of p8 (Tyr31 and Tyr37), and at least one of the two 
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proteins seems to acquire a folded structure. However, it is not known whether the folded-upon-
binding regions involve the whole sequence, or alternatively the acquired structure is highly 
localized, leading to a rather disordered, “fuzzy” complex [124].  
Gastrin precursors and gastrin proteins 
Gastrin precursors and fully amidated gastrin are expressed in 80 % and 25 % of pancreatic 
cancers, respectively [125]. Gastrin is a peptide hormone, which is secreted by the G-cells in the 
gastric antrum and duodenum.  Gastrin acts on the stomach mucosa and on the pancreas to active 
secretion of digestive enzymes. Due to its small size (polypeptide lengths range from 17 to 34 amino 
acids out of the 108 residues of the precursor), there are not reported structural data.  
CONCLUSIONS 
We have reviewed the conformational propensity of unfolded proteins and the fold, domain 
scaffolding, binding-partners and the structure, when available, of those proteins known to intervene 
in PC and involved in signalling pathways. Our description shows that the majority of the proteins 
are multidomain ones. The domains serve as: (i) anchor points to other biomolecules; or (ii) 
phosphorylation sites for protein networks. These results suggest that protein networks are important 
to fully understand PC, and that phosphorylation seems to play key roles in PC development.  
Furthermore, the binding to the corresponding protein or biomolecule by the described protein 
does not alter substantially the overall topology of the isolated proteins, involving only small 
rearrangements around particular side chains of residues. These results pinpoint to the: (i) 
importance of key residues in PC by altering a signal pathway, since the resulting mutants, due to the 
different side-chain of the mutated amino acid, can hamper proper docking of the target; and, (ii) use 
of structural models to design rationally more effective drugs. The amount of data gathered also 
reinforces the importance of protein networks, not only by the existence of key residues at selected 
proteins in the signalling pathway, which may govern protein-biomolecule interactions, but also due 
to the detection of “hub” proteins which are natively unfolded proteins at crucial points of such 
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networks. Finally, the findings reviewed here, indicate that the majority of the proteins involved in 
PC intervene in other types of cancers (since they are involved in general signalling pathways) 
suggesting the absence of specific protein targets for this cancer. This observation might be related 
with the absence of a specific treatment for PC. However, most of the signalling pathways up-
regulated in PC contain proteins with tyrosine kinase domains which might be of therapeutic interest 
either isolated, or by a combined use of future inhibitors that simultaneously target several pathways. 
 
ACKNOWLEDGEMENTS 
We deeply thank both reviewers for their comments and discussions, and Prof. Juan Iovanna 
for suggestions of addition of some proteins to widen the scope of this review. The work of JB in the 
laboratory was supported by Ministerio de Ciencia e Innovación (SAF2008-04048-E, SAF2009-
10667), EVES 2010/189 and CSIC (200820I020). The work of JLN in the laboratory was supported 
by Ministerio de Ciencia e Innovacion (SAF2008-05742-C02-01, CSD2008-00005), Generalitat 
Valenciana (ACOMP2010/114) and FIPSE Foundation (Exp: 36557/06). We deeply thank May 
García, María del Carmen Fuster, Javier Casanova and Raquel Jorquera for assistance. 
 28 
REFERENCES 
1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M.J. (2009) Cancer statistics, 2009. CA 
Cancer J. Clin. 59, 225-249. 
2. Kleeff, J., Michalski, C., Friess, H., and Buchler, M.W. (2006) Pancreatic cancer: from bench to five-
year survival. Pancreas 33, 111-118. 
3. Hidalgo, M. (2010) Pancreatic cancer. New Engl. J. Med. 362, 1605-1617. 
4. Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and DePinho, R.A. (2006) Genetics and 
biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249. 
5. Bardeesy, N., and DePinho, R.A, (2002) Pancreatic cancer biology and genetics. Nature Rev. Cancer 
20, 1218-1249. 
6. Joerger, A.C., and Fersht, A.R, (2008) Structural biology of the tumour suppressor p53. Annu. Rev. 
Biochem. 77, 557-582. 
7. Chang, C., and Werb, Z. (2001) The many faces of metalloproteases: cell growth, invasion, 
angiogenesis and metastasis. Trend Cell. Biol. 11, 37-43. 
8. Skyrova, E., and Fajkus, J. (2009) Structure-function relationships in telomerase genes. Biol. Cell 
101, 375-392. 
9. Wong, H. H., and Lemoine, N. R. (2009) Pancreatic cancer: molecular pathogenesis and new 
therapeutic targets. Nature Rev. Gastroenterol. Hepatol. 6, 412-422. 
10. Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., 
Oien, K. A., Lowy, A. M., Brunton, V.G., Frame, M.C., Jeffry Evans, T. R., and Sansom, O. W. 
(2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. 
Proc. Natl. Acad. Sci. USA 107, 246-251. 
11. Sekaran, V.G., Soares, J., and Jarstfer, M.B. (2010) Structures of telomerase subunits provide 
functional insights. Biochim. Biophys. Acta 1804, 1190-1201 
 29 
12. Autexier, C., and Lue, N.F. (2006) The structure and function of telomerase reverse transcriptase. 
Annu. Rev. Biochem. 75, 493-517. 
13. Giroux, V., Dagorn, J.-C., and Iovanna, J.L. (2009) A review of kinases implicated in pancreatic 
cancer. Pancreatology 9, 738-754. 
14. Furukawa, T., Duguid, W. P., Kobari, M., Matsuno, S., and Tsao, M. S. (1995) Hepatocyte growth 
fact, and Met receptor expression in human pancreatic carcinogenesis. Am. J. Pathol. 147, 889-895. 
15. Nikolaus Schiering, N., Knapp, S., Marconi, M., Flocco, M.M., Cui, J., Perego, R., Rusconi, L., and 
Cristiani, C. (2003). Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor 
receptor c-Met and its complex with the microbial alkaloid K-252a. Proc. Natl. Acad. Sci. USA. 100, 
12654-12659. 
16. Ng, C., Jackson, R.A., Buschdorf, J.P., Sun, Q., Guy, G.R., and Sivaraman, J. (2008) Structural basis 
for a novel intra-peptidyl H-bond and reverse binding of c-Cbl-TKB domain substrates. EMBO J. 
27, 804-816. 
17. Niemann, H.H., Jager, V., Butler, P.J.G., Van Den Heuvel, J., Schmidt, S., Ferraris, D., Gherardi, E., 
and Heinz, D.W. (2007) Structure of the human receptor tyrosine kinase met in complex with the 
listeria invasion protein Inlb. Cell 130, 235-246.  
18. Kozlov, G., Perreault, A., Scharg, J. D., Park, M., Cygler, M., Gehring, K., and Ekiel, I. (2004) 
Insights into function of PSI domains from structure of the Met receptor PSI domain. Biochem. 
Biophys. Res. Commun. 321, 234-240. 
19. Pisegna, J.R., de Weerth, A., Huppi, K., and Wank, S.A. (1992) Molecular cloning of the human 
brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal 
localization. Biochem. Biophys. Res. Commun. 189, 296-303. 
20. Ito, M., Matsui, T., Taniguchi, T., Tsukamoto, T., Murayama, T., Arima, N., Nakata, H., Chiba, T., 
and Chihara, K. (1993) Functional characterization of a human brain cholecystokinin-B receptor. A 
trophic effect of cholecystokinin and gastrin. J. Biol. Chem. 268, 18300-18305. 
 30 
21. Hellmich, M.R., Rui, X.-L., Hellmich, H.L., Fleming, R.Y.D., Evers, B.M., and Townsend, C.M. Jr. 
(2000) Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor 
that stimulates cell growth. J. Biol. Chem. 275, 32122-32128. 
22. Pellegrini, M., and Mierke, D.F, (1999) Molecular complex of cholecystokinin-8 and N-terminus of 
the cholecystokinin A receptor by NMR spectroscopy. Biochemistry 38, 14775-14883. 
23. Giragossian, C., and Mierke, D.F. (2002) Intermolecular interactions between cholecystokinin-8 and 
the third extracellular loop of the cholecystokinin-2 receptor.Biochemistry 41, 4560-4566. 
24. Thayer, S.P., di Magliano, M.P., Heiser, P.W., Nielsen, C.M., Roberts, D.J., Lauwers, G.Y., Qi, 
Y.P., Gysin, S., Fernández-del Castillo, C., Yajnik, V., Antoniu, B., McMahon, M., Warshaw, A.L., 
and Hebrok, M. (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorogenesis. 
Nature 425, 851-856. 
25. Kayed, H., Kleeff, J., Keleg, S., Guo, J., Ketterer, K., Berberat, P.O., Giese, N., Esposito, I., Giese, 
T., Büchler, M.W., and Friess, H. (2004) Indian hedgehog signalling pathway expression and 
regulation in pancreatic cancer. Int. J. Cancer 110, 668-676. 
26. Perler, F. B. (1998) Protein splicing of inteins and hedgehog autoproteolysis: structure, function and 
evolution. Cell 92, 1-4.  
27. Bishop, B., Aricescu, A. R., Harlos, K., O`Callaghan, C.A., Jones, E. Y., and Siebold, C. (2009) 
Structural insights into hedgehog ligand sequestration by the human hedgehog-interacting protein 
HHIP. Nature Struct. Mol. Biol. 16, 698-703. 
28. Bosanac, I., Maun, H.R., Scales, S.J., Wen, X., Lingel, A., Bazan, J.F., de Sauvage, F.J., Hymowitz, 
S.G., and Lazarus, R.A. (2009) The structure of SHH in complex with HHIP reveals a recognition 
role for the Shh pseudo active site in signalling. Nature Struct. Mol. Biol. 16, 691-697. 
29. Cébe-Suarez, S., Pieren, M., Cariolato, L., Arn, S., Hoffmann, U., Bogucki, A., Manlius, C., Wood, 
J., and Ballmer-Hofer, K. (2006) A VEGF-A splice variant defective for heparan sulfate and 
 31 
neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol. Life Sci. 63, 2067-
2077. 
30. Seo, Y., Baba, H. Fukuda, T., Takashima, M., and Sugimachi, K. (2000) High expression of vascular 
endothelial growth factor is associated with liver metastasis and a poor diagnosis for patients with 
ductal pancreatic adenocarcinoma. Cancer 88, 2239-2245. 
31. Stauffer, M.E., Skelton, N.J., and Fairbrothe, W.J. (2002) Refinement of the solution structure of the 
heparin-binding domain of vascular endothelial growth factor using residual dipolar couplings. J. 
Biomol. NMR. 23, 57-61. 
32. Fairbrother, W.J., Champe, M.A., Christinger, H.W., Keyt, B.A., and Starovasnik, M.A. (1998) 
Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 6, 
637-648.  
33. Muller, Y.A., Li, B., Christinger, H.W., Wells, J.A., Cunningham, B.C., and de Vos, A.M. (1997) 
Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain 
receptor binding site. Proc. Natl. Acad. Sci. USA 94, 7192-7197. 
34. Leppänen, V.M., Prota, A.E., Jeltsch, M., Anisimov, A., Kalkkinen, N., Strandin, T., Lankinen, H., 
Goldman, A., Ballmer-Hofer, K., and Alitalo, K. (2010) Structural determinants of growth factor 
binding and specificity by VEGF receptor 2. Proc. Natl. Acad. Sci. USA 107, 2425-2430.  
35. Iyer, S., Leonidas, D.D., Swaminathan, G.J., Maglione, D., Battisti, M., Tucci, M., Persico, M.G., 
and Acharya, K.R. (2001) The crystal structure of human placenta growth factor-1 (PlGF-1), an 
angiogenic protein, at 2.0 Å resolution. J. Biol. Chem. 276, 12153-12161. 
36. Iyer, S., Scotney, P.D., Nash, A.D., and Acharya, K. R. (2006) Crystal structure of human vascular 
endothelial growth factor-B: Identification of amino acids important for receptor binding. J. Mol. 
Biol. 359, 76-85. 
 32 
37. Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H.W., and McKay, P., de Vos, A. M. and 
Lowman, H. B. (1999) Selection and analysis of an optimized anti-VEGF antibody: crystal structure 
of an affinity-matured Fab in complex with antigen , J. Mol. Biol. 293, 865-881. 
38. Pan, B., Li, B., Russell, S.J., Tom, J.Y., Cochran, A.G., and Fairbrother, W.J. (2002) Solution 
structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor. 
J. Mol. Biol. 316, 769-787. 
39. Muller, Y.A., Heiring, C., Misselwitz, R., Welfle, K., and Welfle, H. (2002) The cystine knot 
promotes folding and not thermodynamic stability in vascular endothelial growth factor. J Biol 
Chem. 277, 43410-43416.  
40. Vitt, U.A., Hsu, S.Y., and Hsueh, A.J. (2001) Evolution and classification of cystine knot-containing 
hormones and related extracellular signaling molecules. Mol. Endocrinol. 15, 681-694. 
41. Jeltsch, M., Karpanen, T., Strandin, T., Aho, K., Lankinen, H., and Alitalo, K. (2006) Vascular 
endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and 
feature novel receptor binding patterns. J. Biol. Chem. 281, 12187-12195. 
42. Bishop, J (1985) Oncogenes. 42, 23-28. 
43. Hakam, A., Fang, K., Karl, R., and Coppola, D. (2003) Co-expression of IGF-1R and c-Src proteins 
in human pancreatic ductal adenocarcinoma. Dig. Dis. Sci. 48, 1972-1978. 
44. Yu, H., Rosen, M.K., Shin, T.B., Seidel-Dugan, C., Brugge, J.S., and Schreiber, S.L. (1992) Solution 
structure of the SH3 domain of Src and identification of its ligand binding site. Science 258, 1665-
1668. 
45. Musacchio, A., Saraste, M., and Wilmans, M. (1994) High resolution crystals structures of tyrosine 
kinase SH3 domains complexed with proline-rich peptides. Nature Struct. Biol. 1, 546-551. 
46. Xu, W., Harrison, S.C., and Eck, M.J. (1997) Three-dimensional structure of the tyrosine kinase c-
Src. Nature 385, 595-602. 
 33 
47. Breitenlechner, C.B., Kairies, N.A., Honold, K., Scheiblich, S., Koll, H., Greiter, E., Koch, S., 
Schaefer, W., Huber, R., and Engh, R.A. (2005) Crystal structures of active Src kinase domain 
complexes. J. Mol. Biol. 353, 222-231. 
48. Shewchuk, L., and Jordan, S. (1997) Peptide ligands of pp60(c-src) SH2 domains: a thermodynamic 
and structural study. Biochemistry 36, 6283-6293. 
49. Bloomston, M., Bhardwaj, A., Ellison, E.C., and Frankel, W.-L. (2006) Epidermal growth factor 
receptor expression in pancreatic carcinoma using tissue microarray technique. Dig. Surg. 23, 74-79. 
50. Korc, M., Chandrasekar, B., Yamanaka, Y., Friess, H., Buchier, M., and Beger, H-G. (1992) 
Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated 
with concomitant increases in the levels of epidermal growth factor and transforming growth factor 
alpha. J. Clin. Invest. 90, 1352-1360. 
51. Li, Y., Ren, J., Yu, W., Li, Q., Kuwahara, H., Yin, L., Carraway, K.L. III, and Kufe D. (2001) The 
epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen 
with c-Src and beta-catenin. J. Biol. Chem 276, 35239-35242. 
52. Garrett, T.P., McKern, N. M., Lou, M., Frenkel, M. J., Bentley, J.D., Lovrecz, G. O., Elleman, T. C., 
Cosgrove, L. J., and Ward, C. (1998) Crystal structure of the first three domains of the type-1 
insulin-like growth factor receptor. Nature 394, 395-399. 
53. Kathryn M. Ferguson, K.M., Berger, M.B., Mendrola, J. M., Cho, H.-S., Leahy, D.J., and Lemmon, 
M. A. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain 
dimerization. Mol. Cell 11, 507-517. 
54. Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, 
R.E., Padera, R., Engen, J.R., Wong,K.-K., Eck, M. J., Gray, N.S., and Jänne, P.A. (2009) Novel 
mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462, 1070-1074. 
55. Zhang, X., Gureasko, J., Shen, K., Cole, P.A., and Kuriyan, J. (2006) An allosteric mechanism for 
activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149. 
 34 
56. Burgess, A.W., Cho, H.S., Eigenbrot, C., Ferguson, K.M., Garrett, T.P., Leahy, D.J., Lemmon, 
M.A., Sliwkowski, M.X., Ward, C.W., and Yokoyama, S. (2003) An open-and-shut case? Recent 
insights into the activation of EGF/ErbB receptors. Mol. Cell 12, 541-552. 
57. Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.H., Saito, K., Shirouzu, M., and 
Yokoyama, S. (2002) Crystal structure of the complex of human epidermal growth factor and 
receptor extracellular domains. Cell 110, 775-787. 
58. Zhang, X., Gureasko, J., Shen, K., Cole, P.A., and Kuriyan, J. (2006) An allosteric mechanism for 
activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149. 
59. Zeng, G., Germinaro, M., Micsenyi, A., Monga,N.K., Bell, A., Sood, A., Malhotra, V., Sood, N., 
Midda, V., Monga,D.K., Kokkinakis, D.M., and Monga, S. P. S. (2006) Aberrant Wnt/β-Catenin 
signalling in pancreatic adenocarcinoma. Neoplasia 8, 279-289. 
60. Graham, T.A., Weaver, C., Mao, F., Kimelman, D. and Xu, W. (2000) Crystal structure of a beta-
catenin/Tcf complex. Cell 103, 885-896. 
61. Graham, T.A., Ferkey, D. M., Mao, F. Kimelman, D., and Xu, W. (2001) Tcf4 can specifically 
recognize β-catenin using alternative conformations. Nature Mol. Struct. Biol. 8, 1048-1052. 
62. Graham, T.A., Clements, W.K., Kimelman, D., and Xu, W. (2002) The crystal structure of the beta-
catenin/ICAT complex reveals the inhibitory mechanism of ICAT. Mol. Cell 10, 563-571. 
63. Furuyama, K., Doi, R., Mori, T., Toyoda, E., Ito, D., Kami, K., Koizumi, M., Kida, A., Kawaguchi, 
Y., and Fujimoto, K. (2006) Clinical significance of focal adhesion kinase in resectable pancreatic 
cancer. World J. Surg. 30, 219-226. 
64. Lulo, J., Yuzawa, S., and Schlessinger, J. (2009) Crystal structures of free and ligand-bound focal 
adhesion targeting domain of Pyk2. Biochem. Biophys. Res. Comun. 383, 347-352. 
65. Arold, S.T., Hoellerer, M.K., and Noble, M.E.M. (2002) The structural basis of localization and 
signaling by the focal adhesion targeting domain. Structure 10, 319-327. 
 35 
66. Nowakowski, J., Cronin, C.N., McRee, D.E., Knuth, M.W., Nelson, C.G., Pavletich, N.P., Rodgers, 
J., Sang, B.-C., Scheibe, D.N., Swanson, R.V., and Thompson, D.A. (2002) Structures of the cancer-
related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure 10, 
1659-1667. 
67. Ruggeri, B.A., Huang, L., Wood, M., Cheng, J.Q., and Testa, J.R. (1998) Amplification and 
overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. 
Mol. Carcinog. 21, 81-86. 
68. Rouse, M.B, Seefeld, M.A., Leber, J.D., McNulty, K.C., Sun, L., Miller, W.H., Zhang, S.Y., 
Minthorn, E.A., Concha, N.O., Choudhry, A. E., Schaber, M.D., and Heerding , D. A. (2009) 
Aminofurazans as potent inhibitors of AKT kinase. Bioorganic & Medicinal Chemistry Letters 19, 
1508-1511. 
69. Riddihough, G. (1994) More meanders and sandwiches. Nature Struct. Biol. 1, 755-757. 
70. Tucker, O.N., Dannenberg, A.J., Yang, E.K., Zhang, F., Teng, L., Daly, J.M., Soslow, R.A., 
Masferrer, J.L., Woerner, B.M., Koki, A.T., and Fahey, T.J.- 3rd. (1999) Cyclo-oxygenase-2 is up-
regulated in human pancreatic cancer. Cancer Res. 59, 987-990. 
71. Ding, X.Z., Henning, R., and Adrian, T.E. (2003) Lipoxygenase and cyclooxygenase metabolism: 
new insights into treatment and chemo-prevention of pancreatic cancer. Mol. Cancer 2, 10. 
72. Rimon, G., Sidhu, R.S., Lauver, D.A., Lee, J.Y., Sharma, N.P., Yuan, C., Frieler, R.A, Trievel, R.C., 
Lucchesi, B.R., and Smith, W.L. (2010) Coxibs interfere with the action of aspirin by binding tightly 
to one monomer of cyclooxygenase-1. Proc. Natl. Acad. Sci. USA 107, 28-33. 
73. Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., 
Gildehaus, D., Iyashiro, J. M., Penning, T. D., Seibert, K., Isakson, P. C., and Stallings, W. C. (1996) 
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 
384, 644–648. 
 36 
74. Kiefer, J. R., Pawlitz, J. L., Moreland, K. T., Stegeman, R. A., Hood, W. F., Gierse, J. K., Stevens, 
A. M., Goodwin, D. C., Rowlinson, S. W., Marnett, L.J., Stallings, W. C., and Kurumbail, R. G. 
(2000) Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 445, 97-
101. 
75. Bhattacharyya, D. K., Lecomte, M., Rieke, C. J., Garavito, M., and Smith, W. L. (1996) Involvement 
of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-
phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin 
endoperoxide H synthase-1. J. Biol. Chem. 271, 2179-2184. 
76. Schaffer, M.L., Deshayes, K., Nakamura, G., Sidhu, S., and Skelton, N.J. (2003) Complex with a 
phage display-derived peptide provides insight into the function of insulin-like growth factor I. 
Biochemistry 42, 9324-9334. 
77. Goggins, M., Shekher, M., Turnacioglu, K., Yeo, C.J., Hruban, R.H., and Kern, S.E. (1998) Genetic 
alterations of the transforming growth factor beta receptor genes in pancreatic and biliary 
adenocarcinomas. Cancer Res. 58, 5329-5332. 
78. Shi, Y., Wang, Y.F., Jayaraman, L., Yang, H., Massagué, J., and Pavletich, P. V. (1998) Crystal 
structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signalling. 
Cell 94, 585-594. 
79. Chai, J., Wu, J. W., Yan, N., Massagué, J., Pavletich, N. P., and Shi, Y. (2003) Features of a Smad3 
MH1-DNA complex. Roles of water and zinc in DNA binding. J. Biol. Chem. 278, 20327-20331. 
80. Baburajendran, N., Palasingam, P., Narasimhan, K., Sun, W., Prabhakar, S., Jauch, R., and Kolatkar, 
P. R. (2010) Structure of Smad1 MH1/DNA complex reveals distinctive rearrangements of BMP and 
TGF-β effectors. Nucleic Acids Res. 10, 3477-3488. 
81. Shi, Y., Hata, A., Lo, R.S., Massague, J., and Pavletich, N.P. (1997) A structural basis for mutational 
inactivation of the tumour suppressor Smad4. Nature 388, 87-93. 
 37 
82. Wu, J.W., Krawitz, A.R., Chai, J., Li, W., Zhang, F., Luo, K., and Shi, Y. (2002) Structural 
mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on Ski-mediated 
repression of TGF-beta signalling. Cell 11, 357-367. 
83. Zhang, Y., Musci, T., and Derynck, R. (1997) The tumor suppressor Smad4/DPC 4 as a central 
mediator of Smad function. Cur. Biol. 7, 270-276. 
84. de Caestecker, M.P., Hemmati, P., Larisch-Bloch, S., Ajmera, R., Roberts, A. B., and Lechleider, 
R.J. (1997) Characterization of functional domains within Smad4/DPC4. J. Biol. Chem. 272, 13690-
13696. 
85. Qin, B., Lam, S.S.W., and Lin, K. (1999) Crystal structure of a transcriptionally active Smad4 
fragment. Structure 7, 1493-1503. 
86. Jin, X., Nguyen, D., Zhang, W.-W., Kyritsis, A.P., and Roth, J.A. (1995) Cell cycle arrest and 
inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. 
Cancer Res. 55, 3250-3253.  
87. Serrano, M., Gómez-Lahoz, E., DePinho, R:A., Beach, D., and Bar-Sagi, D. (1995) Inhibition of ras-
induced proliferation and cellular transformation by p16INK4. Science 267, 249-252. 
88. Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R.A. (1996) Role of 
the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37. 
89.Cordon-Cardo, C. (1995) Mutations of cell cycle regulators. Biological and clinical implications for 
human neoplasia. Am. J. Pathol. 147, 545–560. 
90. Caldas, C., Hahn, S.A., da Costa, L.T., Redston, M.S., Schutte, M., Seymour, A.B., Weinstein, C.L., 
Hruban, R.H., Yeo, C.J., and Kern, S.E. (1994) Frequent somatic mutations and homozygous 
deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet. 8, 27-32. 
91. Byeon, I.-J. L., Li, J., Ericson, K., Selby, T. L., Tevelev, A., Kim, H.-J., O'Maille, P., and Tsai, M.-
D. (1998) Tumor suppressor p16INK4A: Determination of solution structure and analyses of its 
interaction with cyclin-dependent kinase 4. Mol. Cell 1, 421-431. 
 38 
92. Russo, A.A., Tong, L. , Lee, J.O., Jeffrey, P.D., and Pavletich, N.P. (1998) Structural basis for 
inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395, 
237-243. 
93. Kahn S., Yamamoto, F., Almoguera, C., Winter, E., Forrester, K., Jordano, J., and Perucho, M. 
(1987) The c-K-ras gene and human cancer. Anticancer Res. 7, 639-652. 
94. Wassarman, D.A., Therrien, M., and Rubin, G.M. (1995) The Ras signalling pathway in Drosophila. 
Cur. Opin. Genet. Dev. 5, 44-50. 
95. Sternberg, P.W., and Han, M. (1998) Genetics of Ras signalling in C. elegans. Trends Genet. 14, 
466-472. 
96. Wittinghofer, A (1998) Signal transduction via Ras. Biol. Chem. 379, 933-937. 
97. Sprang, S. R. (1997) G protein mechanisms: insights from structural analysis. Annu. Rev. Biochem. 
66, 639-678. 
98. Vetter, I. R., and Wittinghofer, A. (1999) Nucleoside triphosphate-binding proteins: different 
scaffolds to achieve phosphoryl transfer. Q. Rev. Biophys. 32, 1-56. 
99. Motojima, K., Urano, T., Nagata, Y., Shiku, H., Tsurifune, T., and Kanematsu, T. (1993) Detection 
of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of 
pancreatic carcinoma. Ann. Surg. 217, 138-143. 
100. Long, S. B., Casey, P. J., and Beese, L. S. (2000) The basis for K-Ras4B binding specificity to 
protein farnesyl-transferase revealed by 2 Å resolution ternary complex structures. Structure 8, 209-
222.  
101. Slebos, R.J., Hoppin, J.A., Tolbert, P.E., Holly, E.A., Brock, J.W., Zhang, R.H., Bracci, P.M., 
Foley, J, Stockton, P., McGregor, L.M., Flake, G.P., and Taylor, J.A. (2000). K-ras and p53 in 
pancreatic cancer: association with medical history, histopathology, and environmental exposures in 
a population-based study. Cancer Epidemiol. Biomarkers Prev. 9, 1223-1232. 
 39 
102. Takai, Y., Sasaki, T., and Matozaki, T. (2001) Small GTP-binding proteins. Physiol. Rev. 81, 153-
208. 
103. Buday, L., and Downward, J. (2008) Many faces of Ras activation. Biochim. Biophys. Acta - 
Reviews on Cancer 1786, 178-187. 
104. Spoerner, M., Prisner, T.F., Bennati, M., Hertel, M.M., Weiden, N., Schweins, T., and Kalbitzer, 
H.R. (2005) Conformational states of human H-Ras detected by high-field EPR, ENDOR, and 31P 
NMR spectroscopy. Magn. Reson. Chem. 43, S74-S83. 
105. Spoerner, M., Nuehs, A., Ganser, P., Herrmann, C., Wittinghofer, A., and Kalbitzer, H.R. (2005) 
Conformational states of Ras complexed with the GTP analogue GppNHp or GppCH2p: 
implications for the interaction with effector proteins. Biochemistry 44, 2225-2236. 
106. Spoerner, M., Herrmann, C., Vetter, I.R., Kalbitzer, H.R., and Wittinghofer, A. (2001) Dynamic 
properties of the Ras switch I region and its importance for binding to effectors. Proc. Natl. Acad. 
Sci. USA 98, 4944-4949. 
107. Dang, T., Vo, K., Wqashington, K., and Berlin, J (2007) The role of Notch 3 signalling pathway in 
pancreatic cancer [abstract]. J. Clin. Oncol. 25, 21049. 
108. Gordon, W. R., Roy, M., Vardar-Ulu, D., Garfinkel, M., Mansour, M.R., Aster, J. C., and 
Blacklow, S. C. (2009) Structure of the Notch 1-negative regulatory region: implications for normal 
activation and pathogenic signalling in T-ALL. Blood 113, 4381-4390. 
109. Keim, V., Rohr, G., Stockert, H.G., and Haberinch, F.J. (1984) An additional secretary protein in 
the rat pancreas. Digestion 29, 242-249. 
110. Christa, L., Carnot, F., Simon, M.T., Levavasseur, F., Strinnakre, M.G., Lasserre, C., Therpot, D., 
Clement, B., Devinoy, E., and Brechot, C. HIP/PAP is an adhesive protein expressed in 
hepatocarcinoma, normal Panteh and pancreatic cells (1996). Am. J. Physiol. 271, G993-G1002. 
111. Closa, D., Motoo, Y., and Iovanna, J.L. (2007) Pancreatitis-associated protein: from a lectin to an 
anti-inflammatory cytokine. World J. Gastroenterol 13, 170-174. 
 40 
112. Xie, M.J., Motoo, Y., Iovanna, J.L., Su, S.B., Ohtsubo, K., Matsubara, F., and Sawabu, N. (2003) 
Overexpression of pancreatitis-associated protein (PAP) in human pancreatic ductal 
adenocarcinoma. Dig. Dis. Sci. 48, 459-464. 
113. Lasserre, C., Christa, L., Simon, M.T., Vernier, P., and Brechot, C. (1992) A novel gene (HIP) 
activated in human primary liver cancer. Cancer Res. 52, 5089-5095.  
114. Demaugre, F., Philippe, Y., Sar, S., Pileire, B., Christa, L., Lasserre, C. and Brechot, C. (2004) 
HIP/PAP, a C-type lectin over-expressed in hepatocellular carcinoma bind the RII alpha regulatory 
subunit of cAMP-dependent kinase and alters the cAMP-dependent protein kinase signalling. Eur. J. 
Biochem. 271, 3812-3820. 
115. Iovanna, J.L., Orelle, B., Keim, V., and Dagorn, J.-C. (1991) Messenger RNA sequence and 
expression of rat pancreatitis-associated protein, a lectin-related protein overexpressed during acute 
experimental pancreatitis. J. Biol. Chem. 266, 24664-24669. 
116. Dusetti, N.J., Frigerio, J.M., Keim, V., Dagorn, J.-C., and Iovanna, J.L. (1993) Structural 
organization of the gene encoding the rat pancreatitis-associated protein. Analysis of its evolutionary 
history reveals an ancient divergence from the other carbohydrate-recognition domain-containing 
genes. J. Biol. Chem. 268, 14470-14475. 
117. Mallo, G. V., Fiedler, F., Calvo, E. L., Ortiz, E. M., Vasseur, S., Keim, V., Morisset, J., and 
Iovanna, J.L. (1997) Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas 
during the acute phase of pancreatitis, pancreatic development, and regeneration, and which 
promotes cellular growth.J. Biol. Chem. 272, 32360-32369. 
118. Goruppi, S., and Iovanna, J.L. (2010) Stress-inducible protein p8 is involved in several 
physiological and pathological processes. J. Biol. Chem. 285, 1577-1581. 
119. Encinar, J.A., Mallo, G.V., Mizyrycki, C., Giono,, L., González-Ros, J.M., Rico, M., Canepa, E., 
Moreno, S., Neira, J.L., and Iovanna, J.L. (2001) Human p8 is a HMG-I/Y-like protein with DNA 
binding activity enhanced by phosphorylation.J. Biol. Chem. 276, 2742-2751. 
 41 
120. Prilusky, J., Felder, C.E., Zeev-Ben-Mordehai, T., Rydberg, E.H., Man, O., Beckmann, J.S., 
Silman, I., and Sussman, J.L. (2005) FoldIndex: a simple tool to predict whether a given protein 
sequence is intrinsically unfolded. Bioinformatics 21, 3435-3438. 
121. Yang, Z.R., Thomson, R., McNeil, P., and Esnouf, M.R. (2005) RONN: the bio-basis function 
neural network technique applied to the detection of natively disordered regions in proteins. 
Bioinformatics 21, 3369-3376. 
122. Gironella, M., Mallicet, C., Cano, C., Sandi, M.J., Hamidi, T., Tauil, R.M., Baston, M., Valaco, P., 
Moreno, S., López, F., Neira, J.L., Dagorn, J.-C., and Iovanna, J.L. (2009) p8/nupr1 regulates DNA-
repair activity after double-strand gamma irradiation-induced DNA damage. J. Cell Physiol. 221, 
594-602. 
123. Malicet, C., Giroux, V., Vasseur, S., Dagorn, J.-C., Neira, J.L., and Iovanna, J.L. (2006) Regulation 
of apoptosis by the p8/prothymosin alpha complex.Proc. Natl. Acad. Sci. USA 103, 2671-2676. 
124. Tompa, P. and Fuxreiter, M. (2008) Fuzzy complexes: polymorphism and structural disorder in 
protein-protein interactions.Trends Biochem. Sci. 33, 2-8. 
125. Caplin, M., Savage, K., Khan, K., Brett, B., Rode, J., Varro, A., and Dhillon, A. (2000) Expression 
and processing of gastrin in pancreatic adenocarcinoma. Br. J. Surg. 87, 1035-1040. 
126. DeLano, W.L. (2002) The PyMOL Molecular Graphics System. DeLano Scientific LLC, San 





FIGURE 1: Structure of the protein tyrosine kinase domain. Tyrosine kinase domains are formed 
by two lobes with the catalytic cleft in-between. The amino-terminal (right lobe) is mostly formed by 
β-strands. Helices are represented as ribbons and strands as arrows. Coordinates have been taken 
from PDB number 1R0P of an HGF receptor structure. The red arrow indicates the movement of the 
α-helix in the amino terminal lobe, which occurs upon phosphorylation. This figure and the following 
ones have been created with Pymol [126].  
 
FIGURE 2: Structure of a cystine-knot. The VEGF structure (PDB number 1BJ1) shows the dimer 
of the antiparallel four-stranded β-sheet monomers covalently linked by intermolecular disulfide 
bonds depicted in yellow. Receptor specificity is determined by the N-terminal α-helix and the three 
loops shown in orange.  
 
FIGURE 3: Structure of a SH3 domain. The structure of a SH3 domain from Src (PDB number 
1FMK) shows the classical β-barrel of five antiparallel β-strands. Both RT loops, connecting strands 
1 an 2 (shown in orange), and the n-Src loops between strands 2 and 3 (shown in purple) are involved 
in recognition of proline-rich ligands. 
 
FIGURE 4: Structure of an armadillo repeat. The β-catenin structure (PDB number 1G3J) shows 
the superhelix of α-helices formed by twelve repeats of three α-helices. Binding of the TCF3 catenin 
binding domain (shown in purple surface representation) takes place through a positively charged 
groove formed by the β-catenin armadillo repeats. 
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FIGURE 5: Structure of a COX-2 protein. The COX-2 protein is mainly an α-helical homodimer 
(PDB number 1CVU). The helical regions are connected by short strands of a twisted β-sheet. The 
arachidonic acid, in the active site, is shown as yellow spheres. 
 
FIGURE 6: In silico analysis of p8 sequence. (A) Distribution of order- and disorder-promoting 
amino acids in the p8 sequence. The distribution shows the deviation in amino acid composition of 
the domain from the average values in the Swiss-Prot data base (as obtained from the World Wide 
Web at http://www.expasy.org/sprot/relnotes/relstat.html). (B) RONN prediction of unstructured 
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